Free Trial
NASDAQ:PSTV

Plus Therapeutics Q1 2025 Earnings Report

Plus Therapeutics logo
$0.19 +0.01 (+3.89%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$0.19 +0.00 (+1.60%)
As of 06/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Plus Therapeutics EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.17
Beat/Miss
Missed by -$0.39
One Year Ago EPS
N/A

Plus Therapeutics Revenue Results

Actual Revenue
$1.06 million
Expected Revenue
$1.11 million
Beat/Miss
Missed by -$53.00 thousand
YoY Revenue Growth
N/A

Plus Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 30, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Plus Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025

Plus Therapeutics Earnings Headlines

When This Happens, You Don’t Wait. You Act.
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Plus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email.

About Plus Therapeutics

Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

View Plus Therapeutics Profile

More Earnings Resources from MarketBeat